BioNTech SE/$BNTX
1D1W1MYTD1Y5YMAX
Capital at risk
About BioNTech SE
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
- Ticker
- $BNTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7,807
- Headquarters
- Mainz, Germany
- Website
- www.biontech.de
BioNTech SE Metrics
BasicAdvanced
$24B
-
-$7.81
1.28
-
Price and volume
Market cap
$24B
Beta
1.28
52-week high
$124.00
52-week low
$79.52
Average daily volume
1.4M
Financial strength
Current ratio
7.848
Quick ratio
7.033
Long term debt to equity
0.015
Total debt to equity
0.018
Interest coverage (TTM)
-127.06%
Profitability
EBITDA (TTM)
-1,585.918
Gross margin (TTM)
76.62%
Net profit margin (TTM)
-63.64%
Operating margin (TTM)
-68.57%
Effective tax rate (TTM)
-3.49%
Revenue per employee (TTM)
$390,500
Management effectiveness
Return on assets (TTM)
-5.41%
Return on equity (TTM)
-9.30%
Valuation
Price to revenue (TTM)
7.823
Price to book
1.36
Price to tangible book (TTM)
1.51
Price to free cash flow (TTM)
46.619
Free cash flow yield (TTM)
2.15%
Free cash flow per share (TTM)
2.061
Growth
Revenue change (TTM)
-7.93%
Earnings per share change (TTM)
374.01%
3-year revenue growth (CAGR)
-33.92%
3-year earnings per share growth (CAGR)
-27.80%
What the Analysts think about BioNTech SE
Analyst ratings (Buy, Hold, Sell) for BioNTech SE stock.
Analyst projections of the future price of BioNTech SE stock.
Bulls say / Bears say
Gotistobart nearly doubled median overall survival to 18.5 months versus 10 months for chemotherapy in previously treated squamous non-small-cell lung cancer. The result gives BioNTech a potentially important late-stage oncology asset, although the pivotal trial is still ongoing. (Reuters, BioNTech)
Pumitamig is moving into a broad late-stage programme, with seven pivotal trials and encouraging early activity in first-line lung cancer across different PD-L1 levels and tumour histologies. Success in even one or more large indications could support BioNTech’s shift from a COVID-led business to a multi-product oncology company. (BioNTech, BioNTech)
Trastuzumab pamirtecan produced a 47.9% confirmed response rate and median progression-free survival of 8.1 months in centrally tested, heavily pre-treated HER2-expressing endometrial-cancer patients. The asset is already in a confirmatory Phase 3 trial, with a potential US filing planned for 2026. (BioNTech, BioNTech)
BioNTech cut its 2026 revenue guidance to €1.6–1.9 billion because COVID-19 vaccine demand is weaker than expected and Germany has existing inventory for the vaccination season. This leaves the company exposed to further declines in its only commercialised product while oncology candidates remain unapproved. (BioNTech, BioNTech)
BioNTech terminated the Phase 2 colorectal-cancer trial of autogene cevumeran after the independent monitoring board identified a numerical overall-survival imbalance and judged that continuing was unlikely to change the efficacy outcome. The setback weakens the case that its individualised mRNA cancer approach can reliably produce clinical benefits. (BioNTech)
BioNTech expects to spend €2.0–2.3 billion on adjusted research and development and €700–800 million on adjusted sales and administration in 2026, against only €1.6–1.9 billion of revenue guidance. That cost base points to continued losses and cash consumption before the late-stage pipeline can generate product sales. (BioNTech)
Data summarised monthly by Lightyear AI. Last updated on 15 Sept 2026.
BioNTech SE Financial Performance
Revenues and expenses
BioNTech SE Earnings Performance
Company profitability
Upcoming events
No upcoming events
BioNTech SE News
AllArticlesVideos
Funds containing BioNTech SE
AllUSDGBPEUR
Fund name | Fund size | $BNTX weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.76% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.76% |
Amundi Prime All Country World€WEBN | €3.2B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.